NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
13 trialsNCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT00668811 2020-08-05
IIT Sutent
Medstar Health Research Institute
Phase 2 Completed
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02713763 2020-03-04
RESUNET
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT00453895 2019-01-31
SIRAC
University of Wuerzburg
Phase 2 Completed
NCT00519896 2017-04-25
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Phase 2 Completed
NCT01121562 2014-06-30
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 2 Completed
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00056693 2008-07-21
Treatment With SU11248 in Patients With Neuroendocrine Tumors
Pfizer
Phase 2 Completed